The Board of Directors has in-depth knowhow in drug development in the pharmaceutical and biotech industry.
Roger M Nitsch serves as CEO & President of Neurimmune. A neuroscientist with a background in medicine, he is recognized as a key opinion leader in neurodegenerative diseases with more than 30 years of experience in Alzheimer’s disease research, and as a pioneer in the development of therapeutic approaches for neurodegenerative diseases. The Potamkin prize winner and Member of the German Academy of Sciences holds a part-time professorship (50%) at the Institute for Regenerative Medicine (IREM), University of Zurich, Switzerland.
Christoph Hock is a board-certified psychiatrist and an internationally recognized expert on Alzheimer's disease and related disorders. He co-founded Neurimmune in 2006, is a member of the board of directors and in addition has been appointed in August 2018 as Chief Medical Officer (CMO). Christoph Hock previously served as Vice-President Medicine and Science at the executive board of the University of Zurich, as professor of Biological Psychiatry at the Medical Faculty, and as member of the Research Council of the Swiss National Science Foundation. He currently holds a part-time professorship at the Institute for Regenerative Medicine (IREM) at the University of Zurich.
Jan Grimm is a neuroscientist with 15 years of experience in drug discovery and development in US and European biotech. Dr. Grimm co-founded Neurimmune in 2006 and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received his PhD from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.